Division of Rheumatology, Allergy, and Immunology, UCSD School of Medicine, La Jolla, CA 92093, USA.
Immunol Rev. 2010 Jan;233(1):233-55. doi: 10.1111/j.0105-2896.2009.00859.x.
Rheumatoid arthritis (RA) remains a significant unmet medical need despite significant therapeutic advances. The pathogenesis of RA is complex and includes many cell types, including T cells, B cells, and macrophages. Fibroblast-like synoviocytes (FLS) in the synovial intimal lining also play a key role by producing cytokines that perpetuate inflammation and proteases that contribute to cartilage destruction. Rheumatoid FLS develop a unique aggressive phenotype that increases invasiveness into the extracellular matrix and further exacerbates joint damage. Recent advances in understanding the biology of FLS, including their regulation regulate innate immune responses and activation of intracellular signaling mechanisms that control their behavior, provide novel insights into disease mechanisms. New agents that target FLS could potentially complement the current therapies without major deleterious effect on adaptive immune responses.
类风湿关节炎 (RA) 尽管在治疗方面取得了重大进展,但仍然存在着巨大的未满足的医疗需求。RA 的发病机制很复杂,包括许多细胞类型,如 T 细胞、B 细胞和巨噬细胞。滑膜衬里中的成纤维样滑膜细胞 (FLS) 通过产生细胞因子来延续炎症,以及产生蛋白酶来破坏软骨,也起着关键作用。类风湿性 FLS 会发展出一种独特的侵袭性表型,增加对细胞外基质的侵袭性,并进一步加剧关节损伤。最近对 FLS 生物学的理解取得了进展,包括它们对先天免疫反应的调节和控制其行为的细胞内信号机制的激活,为疾病机制提供了新的见解。靶向 FLS 的新药物有可能补充目前的治疗方法,而不会对适应性免疫反应产生重大的有害影响。